Two fundraising rounds illustrate selective investor activity: Edinburgh‑based Trogenix closed a $95 million Series A to advance its Odysseus AAV platform aimed at aggressive solid tumors, and Meta‑Flux raised $2 million in seed funding to build an AI and multi‑omics drug discovery platform. Trogenix plans a Q1 2026 clinic entry for its glioblastoma program and described an AAV‑delivered synthetic enhancer strategy that senses tumor cells. Meta‑Flux will use the seed proceeds to develop multiomics integration and validation pipelines, citing participation from pharma executives across major firms. Both rounds show targeted capital allocation toward platform plays that promise translational leverage.